Course Director

Arjun Balar, MD
Arjun Balar, MD

Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York


Petros Grivas
Petros Grivas, MD, PhD

University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Accredited by

Penn State College of Medicine

Activity Description

With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics.

Target Audience

This activity has been designed to meet the educational needs of medical and urologic oncologists, advanced practice clinicians, nurses, pharmacists, and other healthcare providers involved in the interdisciplinary management of patients with bladder cancer.

Educational Objectives

Upon completion of this activity, participants will be able to:
  • Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum
  • Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer
  • Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences
  • Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer
  • Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer

Providership, Credit, and Support

This CME/MOC activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

This CME/MOC activity has been developed in collaboration with the Bladder Cancer Advocacy Network.

This activity is supported by independent educational grants from Astellas and Seattle Genetics, AstraZeneca, Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Merck & Co., Inc.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or Reference course # G6567-20-T.

MOC Statement

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Nursing Education

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Continuing Pharmacy Education

ACPEThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0468-9999-20-003-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Arjun Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York

Arjun Balar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca/MedImmune; Genentech, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co.; Nektar Therapeutics; Pfizer Inc.; and Seattle Genetics, Inc.
Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc.; Immunomedics; Merck & Co., Inc.; Nektar Therapeutics; and Seattle Genetics, Inc. (Research funding to Institution for all except Nektar).
Other Financial or Material Support for Merck & Co., for Steering/Scientific Advisory Committee and Nektar Therapeutics for Steering Committee Membership. AstraZeneca/MedImmune; Genentech, Inc.; and Merck & Co., Inc. for speaking engagements. 

Petros Grivas, MD, PhD
Associate Professor, Department of Medicine, Division of Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Petros Grivas, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Foundation Medicine, Inc.; Genzyme Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and Seattle Genetics, Inc.
Grant/Research Support from Bavarian Nordic; Bristol-Myers Squibb; Clovis Oncology; Debiopharm Group; Immunomedics; and Pfizer, Inc.

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, MLI, has nothing to disclose.
Teresa Haile, RPh, MBA, Lead Pharmacy Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the CNE/CPE accredited provider, the Bladder Cancer Advocacy Network, and PeerView Institute for Medical Education, joint providers, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Janice Trainor-Tellier, MSN, RN
Patricia A. Ensor, RPh, MBA

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing Board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from If you have questions regarding the receipt of your emailed certificate, please contact via email at

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME/MOC credit and 70% or higher to obtain CNE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website:

About This CME/MOC/CNE/CPE Activity

PVI, PeerView Institute for Medical Education, Penn State College of Medicine, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI, Penn State College of Medicine, and Medical Learning Institute, Inc. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. For approved prescribing information, please consult the manufacturer's product labeling. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our activities. No responsibility is taken for errors or omissions in activities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.